PUBLISHER: DataM Intelligence | PRODUCT CODE: 1272772
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1272772
The global periodontal therapeutics market reached US$ 734.8 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 61,459.3 million by 2030. The periodontal therapeutics market is expected to exhibit a CAGR of 9.2% during the forecast period (2023-2030). Adjuvant therapies following the use of antibiotics will support the trend in this market.
The non-surgical treatment procedures for gum disease include the use of antibacterial products and deep cleaning of the mouth which is proven to be sufficient for reversing the periodontal disease in its early stages. Antibiotics including both topical and oral are prescribed for the control of inflammation and plaque of the gum tissue. Oral antibiotics are placed in the gaps formed between gums and teeth by microbial infection, commonly called periodontal pockets.
Periodontal diseases can range from mild to severe and can cause tooth loss if left untreated. The major factors for growth of the global periodontal therapeutics market are the increasing awareness of the importance of oral health, the aging population, and the development of new products and technologies.
Oral hygiene has become one of the most important parameters for staying healthy. Therefore, the growing awareness about oral hygiene is driving the periodontal therapeutics market, specifically in developed countries. The World Health Organization (WHO) states that over 530 million children suffer from dental caries of primary teeth.
Key players such as Procter & Gamble and Colgate-Palmolive Company have undertaken initiatives to spread awareness regarding dental hygiene, both for children and adults, creating demand for periodontal therapeutic drugs. Owing to rising awareness for better oral hygiene, the global periodontal therapeutics market will upscale at a rapid pace over the forecast period.
The partial inefficiency of antibiotics in the treatment of periodontal disease is a key factor limiting the growth of the periodontal therapeutics market. The use of antibiotics in the treatment of gum disease is limited, especially in the later stages of severe periodontitis owing to the low efficiency of treating bacterial infection and healing pockets.
Antibiotic treatment is mostly used in combination with oral surgery or dental cleaning procedures. Furthermore, the overuse and misuse of antibiotics in disease treatment may result in antimicrobial resistance. These factors are expected to hamper the periodontal therapeutics market growth over the forecast period.
The global periodontal therapeutics market has experienced a downturn due to the outbreak of COVID-19. In the first half of 2020, there was a slight decrease in the sales growth of antibiotics used for the treatment of periodontal disease. This can be attributed to a reduction in hospital visits for dental services and a decrease in prescriptions from dentists around the world.
The global periodontal therapeutic market may be indirectly affected by the ongoing conflict between Russia and Ukraine. Economic sanctions imposed on Russia by several countries due to the conflict have led to repercussions in the Russian economy. As a result, the dental healthcare industry, including the periodontal therapeutic market, may be impacted.
The supply of dental equipment from Russia to other countries may be disrupted due to the war, as Russia both imports and exports dental equipment. Additionally, major pharmaceutical companies such as Pfizer, Bayer, and Sanofi have deferred new investments or developments in Russia, which has led to disruptions in the medicine supply chain. These disruptions caused by the conflict have had a negative impact on the global periodontal therapeutics market.
The global periodontal therapeutics market is segmented based on treatment, disease type, distribution channel, and region.
The gingivitis segment is expected to dominate and account for 54.7% of the global periodontal therapeutics market share over the forecast period. Gingivitis is one of the most common types of periodontitis. This is usually caused by poor oral hygiene and red, swollen gums. They also tend to bleed easily.
The treatment of gingivitis focuses on reducing inflammation, removing plaque, and establishing good oral hygiene habits to prevent plaque build-up. Mouthwash, topical antibiotics, or antiseptics may be recommended. For more serious infections or periodontitis, the dentist may recommend oral antibiotics. For instance, over-the-counter medicated toothpaste, mouth rinses, and mouth sprays are very safe, provided they are used as directed. Therefore, this segment growth will boost the global periodontal therapeutics market growth over the forecast period.
North America is expected to have a dominant global periodontal therapeutics market share of around 1/3rd of this market. The U.S. is the largest revenue contributor in North America, and the presence of a large dental workforce in this region indicates its dominance in the global market. For instance, according to the American Dental Association, as of 2022, there are 202,536 professionally active dentists in the U.S. There are 60.8 dentists per 100,000 U.S. population.
The major global players in the market include Kaken Pharmaceutical Co. Ltd., Bausch Health, Colgate-Palmolive, Medicom, Pfizer Inc., 3M, Den-Mat Holdings, LLC, Dentsply Sirona, Xttrium Laboratories, Inc., and Dexcel Pharma.
The global periodontal therapeutics market report would provide approximately 53 tables, 54 figures and 195 Pages.
LIST NOT EXHAUSTIVE